Skip to main content

Table 5 Patient activity as a proxy for survival: role of patient and institutional factors in CML patients (multivariate Cox model)

From: Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program

   Hazard ratio p-value CI 95%
Patient covariates    
 Age <55y 1 (ref)   
  > = 55y 1.42 0.001 [1.16; 1.73]
 Initial phase Chronic 1 (ref)   
  Accelerated form or blast crisis 4.16 <10-4 [1.87; 9.25]
Institutional covariates    
 Research ability   0.55 0.01 [0.35; 0.86]
 Public institution   1.32 0.10 [0.95; 1.84]
 ≥1 hematologist or oncologist   0.88 0.73 [0.44; 1.79]
 Enrollment <2 patients enrolled/y 1(ref)   
  [2–5] patients enrolled/y 0.69 0.09 [0.45; 1.07]
  >5 patients enrolled/y 0.48 <10-4 [0.35; 0.67]
Interaction     
Accelerated form * ≥1 hematologist or oncologist 0.43 0.05 [0.18; 0.99]
  1. Results in bold are statistically significant at the 5% level.
  2. Other non-significant covariates entered in the model: gender, institution's technical competency (bone marrow biopsy or aspiration, Ph + chromosome testing), number of physicians, WHO region.
\